. Referanser
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol, 32(9), 912-918. https://doi.org/10.1200/JCO.2013.53.2069
Aleman, B. M., Raemaekers, J. M., Tirelli, U., Bortolus, R., van 't Veer, M. B., Lybeert, M. L., . . . Treatment of Cancer Lymphoma, G. (2003). Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med, 348(24), 2396-2406. https://doi.org/10.1056/NEJMoa022628
Anderlini, P., Saliba, R., Acholonu, S., Giralt, S. A., Andersson, B., Ueno, N. T., . . . Champlin, R. E. (2008). Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93(2), 257-264. https://doi.org/10.3324/haematol.11828
Anderson, R. A., Remedios, R., Kirkwood, A. A., Patrick, P., Stevens, L., Clifton-Hadley, L., . . . Johnson, P. W. M. (2018). Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol, 19(10), 1328-1337. https://doi.org/10.1016/s1470-2045(18)30500-x
Andre, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., . . . Raemaekers, J. (2017). Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol, 35(16), 1786-1794. https://doi.org/10.1200/JCO.2016.68.6394
Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., . . . Linch, D. C. (2014). Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol, 15(4), 424-435. https://doi.org/10.1016/S1470-2045(14)70027-0
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S. P., . . . Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol, 32(27), 3048-3058. https://doi.org/10.1200/JCO.2013.53.5229
Barzenje, D. A., Cvancarova Småstuen, M., Liestøl, K., Fosså, A., Delabie, J., Kolstad, A., & Holte, H. (2015). Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. PLoS One, 10(7), e0131158. https://doi.org/10.1371/journal.pone.0131158
Barzenje, D. A., Holte, H., Fosså, A., Ghanima, W., Liestøl, K., Delabie, J., & Kolstad, A. (2017). Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leuk Lymphoma, 58(3), 623-632. https://doi.org/10.1080/10428194.2016.1204653
Barzenje, D. A., Kolstad, A., Ghanima, W., & Holte, H. (2018). Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. Hematol Oncol, 36(1), 217-223. https://doi.org/10.1002/hon.2415
Bastings, L., Beerendonk, C. C., Westphal, J. R., Massuger, L. F., Kaal, S. E., van Leeuwen, F. E., . . . Peek, R. (2013). Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update, 19(5), 483-506. https://doi.org/10.1093/humupd/dmt020
Batchelor, T., & Loeffler, J. S. (2006). Primary CNS lymphoma. J Clin Oncol, 24(8), 1281-1288. https://doi.org/10.1200/JCO.2005.04.8819
Behringer, K., Mueller, H., Goergen, H., Thielen, I., Eibl, A. D., Stumpf, V., . . . Borchmann, P. (2013). Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol, 31(2), 231-239. https://doi.org/10.1200/jco.2012.44.3721
Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., . . . Borchmann, P. (2012). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol, 23(7), 1818-1825. https://doi.org/10.1093/annonc/mdr575
Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., . . . Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol, 21(10), 2052-2060. https://doi.org/10.1093/annonc/mdq066
Bennett, M., Sharma, K., Yegena, S., Gavish, I., Dave, H. P., & Schechter, G. P. (2005). Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica, 90(6), 856-858.
Bersvendsen, H., Kolstad, A., Blystad, A. K., Aurlien, E., Fosså, A., Kvaløy, S. O., . . . Lauritzsen, G. F. (2014). Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta oncologica, 53(5), 680-687. https://doi.org/10.3109/0284186X.2013.855816
Bertoni, F., & Zucca, E. (2005). State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol, 23(26), 6415-6420. https://doi.org/10.1200/JCO.2005.05.018
Blaker, Y. N., Eide, M. B., Liestøl, K., Lauritzsen, G. F., Kolstad, A., Fosså, A., . . . Holte, H. (2014). High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma, 55(10), 2319-2327. https://doi.org/10.3109/10428194.2013.871632
Boeckh, M., & Ljungman, P. (2009). How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood, 113(23), 5711-5719. https://doi.org/10.1182/blood-2008-10-143560
Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M., & Pfreundschuh, M. (2009). CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113(17), 3896-3902. https://doi.org/10.1182/blood-2008-10-182253
Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M., . . . German High-Grade Non-Hodgkin's Lymphoma Study, G. (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 18(1), 149-157. https://doi.org/10.1093/annonc/mdl327
Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T. J., Thieblemont, C., . . . Groupe d'Etude des Lymphomes de, l. A. (2007). CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 25(7), 787-792. https://doi.org/10.1200/JCO.2006.07.0722
Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., . . . Engert, A. (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), 2790-2802. https://doi.org/10.1016/S0140-6736(17)32134-7
Borchmann, P., Haverkamp, H., Lohri, A., Mey, U., Kreissl, S., Greil, R., . . . Engert, A. (2017). Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol, 18(4), 454-463. https://doi.org/10.1016/S1470-2045(17)30103-1
Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M. S., . . . Engert, A. (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 22(2), 223-234. https://doi.org/10.1016/S1470-2045(20)30601-X
Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., . . . Costagliola, D. (2006). Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol, 24(25), 4123-4128. https://doi.org/10.1200/JCO.2005.05.4684
Campo, E. (2015). MYC in DLBCL: partners matter. Blood, 126(22), 2439-2440. https://doi.org/10.1182/blood-2015-10-671362
Campo, E. (2017). Pathology and classification of aggressive mature B-cell lymphomas. Hematol Oncol, 35 Suppl 1, 80-83. https://doi.org/10.1002/hon.2406
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., . . . Peterson, B. A. (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 327(21), 1478-1484. https://doi.org/10.1056/NEJM199211193272102
Carter, A., Robison, L. L., Francisco, L., Smith, D., Grant, M., Baker, K. S., . . . Bhatia, S. (2006). Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant, 37(11), 1023-1029. https://doi.org/10.1038/sj.bmt.1705364
Casasnovas, R. O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., . . . Meignan, M. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol, 20(2), 202-215. https://doi.org/10.1016/s1470-2045(18)30784-8
Casulo, C., & Barr, P. M. (2019). How I treat early-relapsing follicular lymphoma. Blood, 133(14), 1540-1547. https://doi.org/10.1182/blood-2018-08-822148
Cavalli, F., Isaacson, P. G., Gascoyne, R. D., & Zucca, E. (2001). MALT Lymphomas. Hematology Am Soc Hematol Educ Program, 241-258.
Chamberlain, M. C., Nolan, C., & Abrey, L. E. (2005). Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol, 75(1), 71-83. https://doi.org/10.1007/s11060-004-8100-y
Cheah, C. Y., Herbert, K. E., O'Rourke, K., Kennedy, G. A., George, A., Fedele, P. L., . . . Seymour, J. F. (2014). A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer, 111(6), 1072-1079. https://doi.org/10.1038/bjc.2014.405
Cheah, C. Y., Wirth, A., & Seymour, J. F. (2014). Primary testicular lymphoma. Blood, 123(4), 486-493. https://doi.org/10.1182/blood-2013-10-530659
Cheson, B. D., Chua, N., Mayer, J., Dueck, G., Trněný, M., Bouabdallah, K., . . . Sehn, L. H. (2018). Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol, 36(22), 2259-2266. https://doi.org/10.1200/JCO.2017.76.3656
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., . . . United Kingdom National Cancer Research, I. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 32(27), 3059-3068. https://doi.org/10.1200/JCO.2013.54.8800
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., . . . Canellos, G. P. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17(4), 1244. https://doi.org/10.1200/JCO.1999.17.4.1244
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., . . . International Harmonization Project on, L. (2007). Revised response criteria for malignant lymphoma. J Clin Oncol, 25(5), 579-586. https://doi.org/10.1200/JCO.2006.09.2403
Coiffier, B. (2006). Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol, 43(4), 213-220. https://doi.org/10.1053/j.seminhematol.2006.07.004
Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., . . . Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346(4), 235-242. https://doi.org/10.1056/NEJMoa011795
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., . . . Group, E.-S. (2018). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med, 378(4), 331-344. https://doi.org/10.1056/NEJMoa1708984
Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., . . . Shepherd, L. E. (2014). Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol, 32(31), 3490-3496. https://doi.org/10.1200/JCO.2013.53.9593
Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., . . . Vogelzang, N. J. (2000). Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist, 5(5), 353-360.
Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., . . . Varns, C. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 17(1), 268-276. https://doi.org/10.1200/JCO.1999.17.1.268
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., . . . Toldbod, H. E. (2012). Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol, 30(25), 3093-3099. https://doi.org/10.1200/JCO.2011.40.2719
Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., . . . Yahalom, J. (2020). Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. International Journal of Radiation Oncology*Biology*Physics, 106(2), 279-281. https://doi.org/https://doi.org/10.1016/j.ijrobp.2019.10.029
Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., . . . Yahalom, J. (2020). ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics, 108(4), 977-978. https://doi.org/https://doi.org/10.1016/j.ijrobp.2020.05.063
Dahl, O., Lehne, G., & Christoffersen, T. (red.). (2016). Medikamentell kreftbehandling: cytostatikaboken (8. utg.). Oslo: Universitetet i Oslo, Avdeling for farmakologi.
Dean, R. M., Fowler, D. H., Wilson, W. H., Odom, J., Steinberg, S. M., Chow, C., . . . Bishop, M. R. (2005). Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant, 11(8), 593-599. https://doi.org/10.1016/j.bbmt.2005.04.005
Dearden, C. (2006). The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol, 33(2 Suppl 5), S44-52. https://doi.org/10.1053/j.seminoncol.2006.01.029
Delabie, J., Holte, H., Vose, J. M., Ullrich, F., Jaffe, E. S., Savage, K. J., . . . Weisenburger, D. D. (2011). Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood, 118(1), 148-155. https://doi.org/10.1182/blood-2011-02-335216
Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., . . . Englert, Y. (2016). No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J Clin Oncol, 34(22), 2568-2574. https://doi.org/10.1200/jco.2015.65.8864
Diamond, C., Taylor, T. H., Im, T., Miradi, M., & Anton-Culver, H. (2006). Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol, 24(3), 139-145. https://doi.org/10.1002/hon.778
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., . . . German Hodgkin's Lymphoma Study, G. (2003). Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348(24), 2386-2395. https://doi.org/10.1056/NEJMoa022473
Diehl, V., Sextro, M., Franklin, J., Hansmann, M. L., Harris, N., Jaffe, E., . . . Stein, H. (1999). Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol, 17(3), 776-783. https://doi.org/10.1200/JCO.1999.17.3.776
Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., & Keul, J. (1999). Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer, 85(10), 2273-2277.
Dorffel, W., Ruhl, U., Luders, H., Claviez, A., Albrecht, M., Bokkerink, J., . . . Schellong, G. (2013). Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol, 31(12), 1562-1568. https://doi.org/10.1200/JCO.2012.45.3266
Dreger, P., Brand, R., Milligan, D., Corradini, P., Finke, J., Lambertenghi Deliliers, G., . . . Chronic Leukemia Working Party of the, E. (2005). Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, 19(6), 1029-1033. https://doi.org/10.1038/sj.leu.2403745
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., . . . Rule, S. (2016). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, 387(10020), 770-778. https://doi.org/10.1016/S0140-6736(15)00667-4
Dundee, J. W., Yang, J., & McMillan, C. (1991). Non-invasive stimulation of the P6 (Neiguan) antiemetic acupuncture point in cancer chemotherapy. J R Soc Med, 84(4), 210-212.
Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015). Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol, 33(32), 3759-3765. https://doi.org/10.1200/JCO.2014.60.3787
Eide, M. B., Lauritzsen, G. F., Kvalheim, G., Kolstad, A., Fagerli, U. M., Maisenholder, M., . . . Holte, H. (2011). High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol, 152(5), 600-610. https://doi.org/10.1111/j.1365-2141.2010.08519.x
Ekstrom-Smedby, K. (2006). Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol, 45(3), 258-271. https://doi.org/10.1080/02841860500531682
Elis, A., Blickstein, D., Klein, O., Eliav-Ronen, R., Manor, Y., & Lishner, M. (2002). Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol, 69(1), 41-44.
Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., . . . German Hodgkin's Study, G. (2005). Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol, 23(22), 5052-5060. https://doi.org/10.1200/JCO.2005.11.080
Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., . . . Diehl, V. (2007). Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol, 25(23), 3495-3502. https://doi.org/10.1200/JCO.2006.07.0482
Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., . . . Diehl, V. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med, 363(7), 640-652. https://doi.org/10.1056/NEJMoa1000067
Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., . . . German Hodgkin's Lymphoma Study, G. (2003). Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 21(19), 3601-3608. https://doi.org/10.1200/JCO.2003.03.023
Evens, A. M., Querfeld, C., & Rosen, S. T. (2006). T-cell non-Hogdkin's lymphoma. Cancer Treat Res, 131, 161-220.
Ezzat, H., Filipenko, D., Vickars, L., Galbraith, P., Li, C., Murphy, K., . . . Leitch, H. A. (2007). Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials, 8(3), 132-144. https://doi.org/10.1310/hct0803-132
Ezzo, J., Vickers, A., Richardson, M. A., Allen, C., Dibble, S. L., Issell, B., . . . Zhang, G. (2005). Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol, 23(28), 7188-7198. https://doi.org/10.1200/JCO.2005.06.028
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., . . . Solal-Celigny, P. (2009). Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol, 27(27), 4555-4562. https://doi.org/10.1200/JCO.2008.21.3991
Ferreri, A. J., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., . . . International Extranodal Lymphoma Study, G. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol, 3(5), e217-227. https://doi.org/10.1016/S2352-3026(16)00036-3
Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., . . . International Extranodal Lymphoma Study, G. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374(9700), 1512-1520. https://doi.org/10.1016/S0140-6736(09)61416-1
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., . . . International Extranodal Lymphoma Study, G. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol, 4(11), e510-e523. https://doi.org/10.1016/S2352-3026(17)30174-6
Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., . . . Miller, T. P. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328(14), 1002-1006. https://doi.org/10.1056/NEJM199304083281404
Fløisand, Y., Brinch, L., Gedde-Dahl, T., Tjønnfjord, G. E., Dybedal, I., Holte, H., . . . Kolstad, A. (2012). Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 47(12), 1552-1557. https://doi.org/10.1038/bmt.2012.63
Foss Abrahamsen, A., Andersen, A., Nome, O., Jacobsen, A. B., Holte, H., Foss Abrahamsen, J., & Kvaløy, S. (2002). Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol, 13(11), 1786-1791.
Fossa, A., Fiskvik, I. H., Kolstad, A., Lauritzsen, G. F., Aurlien, E., Blystad, A. K., . . . Holte, H. (2012). Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Ann Oncol, 23(5), 1254-1259. https://doi.org/10.1093/annonc/mdr385
Fossa, A., Smeland, K., Fagerli, U. M., Galleberg, R. B., Bersvendsen, H. S., & Holte, H. (2020). Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016. Acta Oncol, 59(1), 101-105. https://doi.org/10.1080/0284186X.2019.1652765
Gang, A. O., Strøm, C., Pedersen, M., d'Amore, F., Pedersen, L. M., Bukh, A., . . . d Nully Brown, P. (2012). R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol, 23(1), 147-153. https://doi.org/10.1093/annonc/mdr058
Garnock-Jones, K. P. (2013). Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs, 73(4), 371-381. https://doi.org/10.1007/s40265-013-0031-5
Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M., & Abrey, L. E. (2006). Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol, 24(28), 4570-4574. https://doi.org/10.1200/JCO.2006.06.6910
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., . . . Nordic Lymphoma, G. (2008). Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112(7), 2687-2693. https://doi.org/10.1182/blood-2008-03-147025
Girbl, T., Lunzer, V., Greil, R., Namberger, K., & Hartmann, T. N. (2014). The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Transfusion, 54(9), 2325-2335. https://doi.org/10.1111/trf.12632
Gjerstad, L., Skjeldal, O. H., & Helseth, H. (red.). (2003). Nevrologi og nevrokirurgi: fra barn til voksen: undersøkelse, diagnose, behandling (3. utg.). Nesbru: Vett & viten.
Glenny, A. M., Fernandez Mauleffinch, L. M., Pavitt, S., & Walsh, T. (2009). Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev, (1), CD006706. https://doi.org/10.1002/14651858.CD006706.pub2
Goldkuhl, C., Ekman, T., Wiklund, T., Telhaug, R., & Nordic Lymphoma, G. (2002). Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study. Acta Oncol, 41(1), 29-35.
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., . . . Salles, G. A. (2014). PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med, 370(11), 1008-1018. https://doi.org/10.1056/NEJMoa1314583
Gospodarowicz, M. Personlig meddelelse.
Guadagnolo, B. A., Punglia, R. S., Kuntz, K. M., Mauch, P. M., & Ng, A. K. (2006). Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol, 24(25), 4116-4122. https://doi.org/10.1200/JCO.2006.07.0409
Han, J. J., Kim, T. M., Jeon, Y. K., Kim, M. K., Khwarg, S. I., Kim, C. W., . . . Heo, D. S. (2015). Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol, 94(4), 575-581. https://doi.org/10.1007/s00277-014-2240-8
Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339(21), 1506-1514. https://doi.org/10.1056/NEJM199811193392104
Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., . . . European Mantle Cell Lymphoma, N. (2016). Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, 388(10044), 565-575. https://doi.org/10.1016/S0140-6736(16)00739-X
Herrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., . . . Armand, P. (2017). Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol, 35(1), 24-31. https://doi.org/10.1200/JCO.2016.68.2740
Hertzberg, M., Grigg, A., Gottlieb, D., Szer, J., Roberts, A., Hoyt, R., . . . Bradstock, K. F. (2006). Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant, 37(10), 923-928. https://doi.org/10.1038/sj.bmt.1705357
Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., . . . Unterhalt, M. (2005). Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106(12), 3725-3732. https://doi.org/10.1182/blood-2005-01-0016
Hill, Q. A., & Owen, R. G. (2006). CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev, 20(6), 319-332. https://doi.org/10.1016/j.blre.2006.02.001
Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., . . . German Multicenter Study Group for Adult Acute Lymphoblastic, L. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-3879. https://doi.org/10.1182/blood-2014-03-563627
Holland, J. C., & Reznik, I. (2005). Pathways for psychosocial care of cancer survivors. Cancer, 104(11 Suppl), 2624-2637. https://doi.org/10.1002/cncr.21252
Hollender, A., Kvaloy, S., Lote, K., Nome, O., & Holte, H. (2000). Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer, 36(14), 1762-1768.
Holte, H., Leppä, S., Björkholm, M., Fluge, O., Jyrkkiö, S., Delabie, J., . . . Eriksson, M. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol, 24(5), 1385-1392. https://doi.org/10.1093/annonc/mds621
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., . . . Trümper, L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 393(10168), 229-240. https://doi.org/10.1016/s0140-6736(18)32984-2
Hoskin, P. J., Diez, P., Williams, M., Lucraft, H., Bayne, M., & Participants of the Lymphoma Radiotherapy, G. (2013). Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol), 25(1), 49-58. https://doi.org/10.1016/j.clon.2012.07.011
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., . . . European Mantle Cell Lymphoma, N. (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111(2), 558-565. https://doi.org/10.1182/blood-2007-06-095331
Hoster, E., Rosenwald, A., Berger, F., Bernd, H. W., Hartmann, S., Loddenkemper, C., . . . Klapper, W. (2016). Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol, 34(12), 1386-1394. https://doi.org/10.1200/JCO.2015.63.8387
Haas, R. L., Poortmans, P., de Jong, D., Aleman, B. M., Dewit, L. G., Verheij, M., . . . Bartelink, H. (2003). High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol, 21(13), 2474-2480. https://doi.org/10.1200/JCO.2003.09.542
Haas, R. L., Poortmans, P., de Jong, D., Verheij, M., van der Hulst, M., de Boer, J. P., & Bartelink, H. (2005). Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer, 41(12), 1724-1730. https://doi.org/10.1016/j.ejca.2005.04.033
Jantunen, E., & Varmavuo, V. (2014). Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert Opin Biol Ther, 14(6), 851-861. https://doi.org/10.1517/14712598.2014.902927
Jerkeman, M., Anderson, H., Cavallin-Stahl, E., Dictor, M., Hagberg, H., Johnson, A., . . . Akerman, M. (1999). CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol, 10(9), 1079-1086.
Jerkeman, M., Leppä, S., Kvaløy, S., & Holte, H. (2004). ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol, 73(3), 179-182. https://doi.org/10.1111/j.1600-0609.2004.00294.x
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., . . . Horsman, D. E. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114(11), 2273-2279. https://doi.org/10.1182/blood-2009-03-212191
Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., . . . Barrington, S. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med, 374(25), 2419-2429. https://doi.org/10.1056/NEJMoa1510093
Jones, G. W., Kacinski, B. M., Wilson, L. D., Willemze, R., Spittle, M., Hohenberg, G., . . . Knobler, R. (2002). Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology, 47(3), 364-370. https://doi.org/https://doi.org/10.1067/mjd.2002.123482
Juweid, M. E., & Cheson, B. D. (2005). Role of positron emission tomography in lymphoma. J Clin Oncol, 23(21), 4577-4580. https://doi.org/10.1200/JCO.2005.01.904
Juweid, M. E., & Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. N Engl J Med, 354(5), 496-507. https://doi.org/10.1056/NEJMra050276
Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., . . . Horning, S. J. (2014). Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol, 32(28), 3096-3102. https://doi.org/10.1200/JCO.2014.56.5853
Kamstrup, M. R., Gniadecki, R., Iversen, L., Skov, L., Petersen, P. M., Loft, A., & Specht, L. (2015). Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys, 92(1), 138-143. https://doi.org/10.1016/j.ijrobp.2015.01.047
Kansara, R., Villa, D., Gerrie, A. S., Klasa, R., Shenkier, T., Scott, D. W., . . . Savage, K. J. (2017). Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. Br J Haematol, 179(3), 508-510. https://doi.org/10.1111/bjh.14229
Kaplan, L. D., Lee, J. Y., Ambinder, R. F., Sparano, J. A., Cesarman, E., Chadburn, A., . . . Scadden, D. T. (2005). Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106(5), 1538-1543. https://doi.org/10.1182/blood-2005-04-1437
Kasenda, B., Loeffler, J., Illerhaus, G., Ferreri, A. J. M., Rubenstein, J., & Batchelor, T. T. (2016). The role of whole brain radiation in primary CNS lymphoma. Blood, 128(1), 32-36. https://doi.org/10.1182/blood-2016-01-650101
Kasenda, B., Schorb, E., Fritsch, K., Finke, J., & Illerhaus, G. (2012). Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol, 23(10), 2670-2675. https://doi.org/10.1093/annonc/mds059
Khouri, I. F., Lee, M. S., Saliba, R. M., Jun, G., Fayad, L., Younes, A., . . . Champlin, R. E. (2003). Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol, 21(23), 4407-4412. https://doi.org/10.1200/JCO.2003.05.501
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., . . . Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol, 33(32), 3750-3758. https://doi.org/10.1200/JCO.2014.60.3969
Kimby, E., Ostenstad, B., Brown, P., Hagberg, H., Erlanson, M., Holte, H., . . . Nordic Lymphoma, G. (2015). Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma, 56(9), 2598-2607. https://doi.org/10.3109/10428194.2015.1014363
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., . . . Dreyling, M. H. (2012). Treatment of older patients with mantle-cell lymphoma. N Engl J Med, 367(6), 520-531. https://doi.org/10.1056/NEJMoa1200920
Knols, R., Aaronson, N. K., Uebelhart, D., Fransen, J., & Aufdemkampe, G. (2005). Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol, 23(16), 3830-3842. https://doi.org/10.1200/JCO.2005.02.148
Koch, P., Grothaus-Pinke, B., Hiddemann, W., Willich, N., Reers, B., del Valle, F., . . . Tiemann, M. (1997). Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL. Ann Oncol, 8 Suppl 1, 85-88.
Kolstad, A., Holte, H., Fossa, A., Lauritzsen, G. F., Gaustad, P., & Torfoss, D. (2007). Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica, 92(1), 139-140.
Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., . . . Nordic Lymphoma, G. (2014). Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood, 123(19), 2953-2959. https://doi.org/10.1182/blood-2013-12-541953
Kolstad, A., Nome, O., Delabie, J., Lauritzsen, G. F., Fossa, A., & Holte, H. (2007). Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma, 48(3), 570-576. https://doi.org/10.1080/10428190601126610
Korfel, A., Thiel, E., Martus, P., Mohle, R., Griesinger, F., Rauch, M., . . . Weller, M. (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12), 1242-1248. https://doi.org/10.1212/WNL.0000000000001395
Kristinsson, S. Y., Goldin, L. R., Bjorkholm, M., Koshiol, J., Turesson, I., & Landgren, O. (2009). Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica, 94(11), 1581-1589. https://doi.org/10.3324/haematol.2009.008979
Kumar, A., Vanderplas, A., LaCasce, A. S., Rodriguez, M. A., Crosby, A. L., Lepisto, E., . . . Abel, G. A. (2012). Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer, 118(11), 2944-2951. https://doi.org/10.1002/cncr.26588
Kusumi, E., Kami, M., Kanda, Y., Murashige, N., Kishi, Y., Suzuki, R., . . . Takaue, Y. (2005). Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant, 36(3), 205-213. https://doi.org/10.1038/sj.bmt.1705027
Kwong, Y. L., Kim, W. S., Lim, S. T., Kim, S. J., Tang, T., Tse, E., . . . Chim, C. S. (2012). SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 120(15), 2973-2980. https://doi.org/10.1182/blood-2012-05-431460
Lagerlöf, I., Holte, H., Glimelius, I., Björkholm, M., Enblad, G., Erlanson, M., . . . Molin, D. (2020). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol, 188(5), 685-691. https://doi.org/10.1111/bjh.16232
Lambertini, M., Peccatori, F. A., Demeestere, I., Amant, F., Wyns, C., Stukenborg, J. B., . . . Jordan, K. (2020). Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(†). Ann Oncol. https://doi.org/10.1016/j.annonc.2020.09.006
Larsen, I. K. (red.). (2016). Cancer in Norway 2015: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin-2015-special-issue.pdf
Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., . . . Group, L. (2017). Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med, 377(13), 1250-1260. https://doi.org/10.1056/NEJMoa1701769
Lekovich, J., Lobel, A. L. S., Stewart, J. D., Pereira, N., Kligman, I., & Rosenwaks, Z. (2016). Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet, 33(5), 657-662. https://doi.org/10.1007/s10815-016-0689-1
Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., . . . Hiddemann, W. (2005). Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 23(9), 1984-1992. https://doi.org/10.1200/JCO.2005.08.133
Levernes, S., & Johannessen, D. C. (2003). Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering (StrålevernRapport 2003:12 ). Østerås: Statens strålevern. Hentet fra https://www.nrpa.no/publikasjon/straalevernrapport-2003-12-volum-og-doser-ved-straalebehandling-definisjoner-retningslinjer-for-bruk-dokumentasjon-og-rapportering.pdf
Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., . . . Lu, S. C. (2012). Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol, 91(11), 1741-1745. https://doi.org/10.1007/s00277-012-1508-0
Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., . . . Hudson, G. V. (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341(8852), 1051-1054.
Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., . . . Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7(11), 1630-1636. https://doi.org/10.1200/JCO.1989.7.11.1630
Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S., Thiede, C., . . . Du, M. Q. (2002). T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology, 122(5), 1286-1294.
Ljungman, P., Cordonnier, C., Einsele, H., Englund, J., Machado, C. M., Storek, J., . . . Prevention. (2009). Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant, 44(8), 521-526. https://doi.org/10.1038/bmt.2009.263
Lofthus, A. S., & Allen, S. M. (2006). Kan transkutan elektrisk nervestimulering lindre nevropatisk smerte? Fysioterapeuten, 73(4), 16-25.
Loge, J. H., Abrahamsen, A. F., Ekeberg, O., & Kaasa, S. (1999). Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol, 17(1), 253-261. https://doi.org/10.1200/JCO.1999.17.1.253
Lok, A. S. F., & Bonis, P. A. L. (18. desember 2017). Hepatitis B virus reactivation associated with immunosuppressive therapy. [database]. Waltham, MA: UpToDate, Inc. Hentet 10. desember 2018
Lote, K., Holte, H., Nome, O., Langholm, R., & Kvaløy, S. (2000). Stage I high-grade non-Hodgkin's lymphoma. Acta oncologica, 39(7), 865-872.
Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., . . . Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol, 100(1), 86-92. https://doi.org/10.1016/j.radonc.2011.05.013
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., . . . Hiddemann, W. (2017). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med, 377(14), 1331-1344. https://doi.org/10.1056/NEJMoa1614598
Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J., Maziarz, R. T., . . . Maloney, D. G. (2004). Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 104(12), 3535-3542. https://doi.org/10.1182/blood-2004-06-2275
Martelli, M., Ferreri, A. J., & Johnson, P. (2008). Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol, 68(3), 256-263. https://doi.org/10.1016/j.critrevonc.2008.07.020
Martinelli, G., Schmitz, S. F., Utiger, U., Cerny, T., Hess, U., Bassi, S., . . . Ghielmini, M. (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol, 28(29), 4480-4484. https://doi.org/10.1200/JCO.2010.28.4786
Mauch, P. (2001). Follicular non-Hodgkin's lymphoma: the role of radiation therapy. Ann Hematol, 80 Suppl 3, B63-65.
Mehra, T., Ikenberg, K., Moos, R. M., Benz, R., Nair, G., Schanz, U., . . . Cozzio, A. (2015). Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA Dermatol, 151(1), 73-77. https://doi.org/10.1001/jamadermatol.2014.1629
Meissner, J., Tichy, D., Dietrich, S., Schmitt, T., Ziepert, M., Kuhnt, E., . . . Ho, A. D. (2014). Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br J Haematol, 166(4), 612-615. https://doi.org/10.1111/bjh.12877
Meissner, J., Tichy, D., Katzke, V., Kühn, T., Dietrich, S., Schmitt, T., . . . Ho, A. D. (2015). Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol, 26(8), 1771-1776. https://doi.org/10.1093/annonc/mdv227
Melchers, R. C., Willemze, R., Daniëls, L. A., Neelis, K. J., Bekkenk, M. W., de Haas, E. R. M., . . . Quint, K. D. (2017). Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International Journal of Radiation Oncology*Biology*Physics, 99(5), 1279-1285. https://doi.org/https://doi.org/10.1016/j.ijrobp.2017.08.010
Melsack, R., & Wall, P. D. E. (red.). (1999). Textbook of pain (4. utg.). Edinburgh Churchill Livingstone.
Mirza, M. R., & Brincker, H. (1991). MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta Oncol, 30(1), 17-21.
Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., . . . Mackinnon, S. (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), 3865-3871. https://doi.org/10.1182/blood-2004-03-1105
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., . . . Omuro, A. (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol, 31(31), 3971-3979. https://doi.org/10.1200/JCO.2013.50.4910
Moskowitz, A. J., Lunning, M. A., & Horwitz, S. M. (2014). How I treat the peripheral T-cell lymphomas. Blood, 123(17), 2636-2644. https://doi.org/10.1182/blood-2013-12-516245
Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S., Coady-Lyons, N., . . . Zelenetz, A. D. (1999). Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol, 17(12), 3776-3785. https://doi.org/10.1200/JCO.1999.17.12.3776
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., . . . Group, A. S. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 385(9980), 1853-1862. https://doi.org/10.1016/S0140-6736(15)60165-9
Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J. B., . . . Gisselbrecht, C. (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 107(10), 3832-3840. https://doi.org/10.1182/blood-2005-09-3600
Nakamura, S., Ye, H., Bacon, C. M., Goatly, A., Liu, H., Banham, A. H., . . . Du, M. Q. (2007). Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut, 56(10), 1358-1363. https://doi.org/10.1136/gut.2007.123729
Nasjonal behandlingstjeneste for fertilitetsbevarende behandling med autologt ovarialvev. .Hentet 17.11, 2020, fra https://oslo-universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/nasjonal-behandlingstjeneste-for-fertilitetsbevarende-behandling-med-autologt-ovarialvev
Nasjonal helseplan (2007-2010). (2006). (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Hentet fra http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf
Nasjonalt handlingsprogram for palliasjon i kreftomsorgen. (2015). (IS-2285). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen
Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av lungekreft, mesoteliom og thymom. (2018). (IS-2745). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-lungekreft-mesoteliom-og-thymom
Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. (2018). (IS-2736). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-pasienter-med-brystkreft
Ohkubo, Y., Saito, Y., Ushijima, H., Onishi, M., Kazumoto, T., Saitoh, J. I., . . . Kurosumi, M. (2017). Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years. J Radiat Res, 58(4), 537-542. https://doi.org/10.1093/jrr/rrw044
Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., . . . Loren, A. W. (2018). Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 36(19), 1994-2001. https://doi.org/10.1200/jco.2018.78.1914
Omuro, A., Correa, D. D., DeAngelis, L. M., Moskowitz, C. H., Matasar, M. J., Kaley, T. J., . . . Sauter, C. S. (2015). R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 125(9), 1403-1410. https://doi.org/10.1182/blood-2014-10-604561
Ozsahin, M., Tsang, R. W., Poortmans, P., Belkacemi, Y., Bolla, M., Dincbas, F. O., . . . Zouhair, A. (2006). Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys, 64(1), 210-217. https://doi.org/10.1016/j.ijrobp.2005.06.039
Pakkeforløp for lymfomer. (2016). (IS-2509). Oslo: Helsedirektoratet. Hentet fra https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-lymfomer
Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J. F., Castaigne, S., . . . Groupe d'Etude des Lymphomes de l'Adulte, i. (2011). Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol, 12(5), 460-468. https://doi.org/10.1016/S1470-2045(11)70069-9
Pfreundschuh, M. (2005). Mature T-cell and NK/T-cell neoplasms. Clin Adv Hematol Oncol, 3(11), suppl 8-9.
Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., . . . German High-Grade Non-Hodgkin Lymphoma Study, G. (2008). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol, 9(2), 105-116. https://doi.org/10.1016/S1470-2045(08)70002-0
Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rube, C., . . . German High-Grade Non-Hodgkin's Lymphoma Study, G. (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104(3), 634-641. https://doi.org/10.1182/blood-2003-06-2095
Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rudolph, C., . . . German High-Grade Non-Hodgkin's Lymphoma Study, G. (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104(3), 626-633. https://doi.org/10.1182/blood-2003-06-2094
Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., . . . MabThera International Trial, G. (2006). CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7(5), 379-391. https://doi.org/10.1016/S1470-2045(06)70664-7
Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., . . . et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333(23), 1540-1545. https://doi.org/10.1056/NEJM199512073332305
Picardi, M., De Renzo, A., Pane, F., Nicolai, E., Pacelli, R., Salvatore, M., & Rotoli, B. (2007). Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma, 48(9), 1721-1727. https://doi.org/10.1080/10428190701559140
Poeschel, V., Held, G., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., . . . German Lymphoma, A. (2020). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, 394(10216), 2271-2281. https://doi.org/10.1016/S0140-6736(19)33008-9
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., . . . group, A. s. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094), 555-566. https://doi.org/10.1016/S0140-6736(17)31266-7
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., . . . Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol, 30(18), 2190-2196. https://doi.org/10.1200/JCO.2011.38.0402
Pulczynski, E. J., Kuittinen, O., Erlanson, M., Hagberg, H., Fosså, A., Eriksson, M., . . . Fagerli, U. M. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica, 100(4), 534-540. https://doi.org/10.3324/haematol.2014.108472
Quasthoff, S., & Hartung, H. P. (2002). Chemotherapy-induced peripheral neuropathy. J Neurol, 249(1), 9-17.
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grunhagen, U., Losem, C., . . . Study group indolent, L. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381(9873), 1203-1210. https://doi.org/10.1016/S0140-6736(12)61763-2
Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., . . . Tilly, H. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377(9759), 42-51. https://doi.org/10.1016/S0140-6736(10)62175-7
Sankila, R., Garwicz, S., Olsen, J. H., Dollner, H., Hertz, H., Kreuger, A., . . . Tulinius, H. (1996). Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol, 14(5), 1442-1446. https://doi.org/10.1200/JCO.1996.14.5.1442
Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., . . . Balzarotti, M. (2007). Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92(1), 35-41.
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., . . . Gascoyne, R. D. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114(17), 3533-3537. https://doi.org/10.1182/blood-2009-05-220095
Savage, K. J., Skinnider, B., Al-Mansour, M., Sehn, L. H., Gascoyne, R. D., & Connors, J. M. (2011). Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 118(17), 4585-4590. https://doi.org/10.1182/blood-2011-07-365932
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., . . . Marrow, T. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359(9323), 2065-2071. https://doi.org/10.1016/S0140-6736(02)08938-9
Schmitz, N., Zeynalova, S., Glass, B., Kaiser, U., Cavallin-Stahl, E., Wolf, M., . . . Pfreundschuh, M. (2012). CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol, 23(5), 1267-1273. https://doi.org/10.1093/annonc/mdr440
Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., . . . Savage, K. J. (2016). CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol, 34(26), 3150-3156. https://doi.org/10.1200/JCO.2015.65.6520
Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnsen, H. E., . . . Kvalheim, G. (2003). High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21(21), 3918-3927. https://doi.org/10.1200/JCO.2003.10.023
Schulz, H., Rehwald, U., Morschhauser, F., Elter, T., Driessen, C., Rudiger, T., . . . Reiser, M. (2008). Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 111(1), 109-111. https://doi.org/10.1182/blood-2007-03-078725
Schüring, A. N., Fehm, T., Behringer, K., Goeckenjan, M., Wimberger, P., Henes, M., . . . von Wolff, M. (2018). Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Arch Gynecol Obstet, 297(1), 241-255. https://doi.org/10.1007/s00404-017-4594-3
Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., . . . Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857-1861. https://doi.org/10.1182/blood-2006-08-038257
Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., . . . Cheson, B. D. (2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol, 17(8), 1081-1093. https://doi.org/10.1016/S1470-2045(16)30097-3
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., . . . Matasar, M. J. (2020). Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol, 38(2), 155-165. https://doi.org/10.1200/JCO.19.00172
Sesques, P., & Johnson, N. A. (2017). Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood, 129(3), 280-288. https://doi.org/10.1182/blood-2016-02-636316
Shah, G. D., Yahalom, J., Correa, D. D., Lai, R. K., Raizer, J. J., Schiff, D., . . . Abrey, L. E. (2007). Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol, 25(30), 4730-4735. https://doi.org/10.1200/JCO.2007.12.5062
Smeland, S., Blystad, A. K., Kvaløy, S. O., Ikonomou, I. M., Delabie, J., Kvalheim, G., . . . Holte, H. (2004). Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol, 15(7), 1072-1078. https://doi.org/10.1093/annonc/mdh262
Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O., Arranz-Saez, R., . . . Montserrat, E. (2004). Follicular lymphoma international prognostic index. Blood, 104(5), 1258-1265. https://doi.org/10.1182/blood-2003-12-4434
Soutar, R., Lucraft, H., Jackson, G., Reece, A., Bird, J., Low, E., . . . British Society for, H. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol, 124(6), 717-726.
Sparano, J. A. (2007). HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol, 19(5), 458-463. https://doi.org/10.1097/CCO.0b013e3282c8c835
Specht, L., Dabaja, B., Illidge, T., Wilson, L. D., & Hoppe, R. T. (2015). Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys, 92(1), 32-39. https://doi.org/10.1016/j.ijrobp.2015.01.008
Stein, H., Foss, H. D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., . . . Falini, B. (2000). CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood, 96(12), 3681-3695.
Suarez, F., Lortholary, O., Hermine, O., & Lecuit, M. (2006). Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood, 107(8), 3034-3044. https://doi.org/10.1182/blood-2005-09-3679
Sureda, A., Robinson, S., Canals, C., Carella, A. M., Boogaerts, M. A., Caballero, D., . . . Schmitz, N. (2008). Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 26(3), 455-462. https://doi.org/10.1200/JCO.2007.13.2415
Sweetenham, J. W., Santini, G., Qian, W., Guelfi, M., Schmitz, N., Simnett, S., . . . Goldstone, A. H. (2001). High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol, 19(11), 2927-2936. https://doi.org/10.1200/JCO.2001.19.11.2927
Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., & Thiele, J. (red.). (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4. rev. utg.). (WHO Classification of Tumours, Volume 2). Lyon: IARC.
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., . . . Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375-2390. https://doi.org/10.1182/blood-2016-01-643569
Thieblemont, C., & Coiffier, B. (2006). Management of marginal zone lymphomas. Curr Treat Options Oncol, 7(3), 213-222.
Thieblemont, C., & Zucca, E. (2017). Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best Pract Res Clin Haematol, 30(1-2), 109-117. https://doi.org/10.1016/j.beha.2017.01.002
Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., . . . Whittaker, S. (2006). EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer, 42(8), 1014-1030. https://doi.org/10.1016/j.ejca.2006.01.025
Tsai, H. K., & Mauch, P. M. (2007). Nodular lymphocyte-predominant hodgkin lymphoma. Semin Radiat Oncol, 17(3), 184-189. https://doi.org/10.1016/j.semradonc.2007.02.004
Tsang, R. W., Campbell, B. A., Goda, J. S., Kelsey, C. R., Kirova, Y. M., Parikh, R. R., . . . Yahalom, J. (2018). Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys, 101(4), 794-808. https://doi.org/10.1016/j.ijrobp.2018.05.009
Tsang, R. W., & Gospodarowicz, M. K. (2007). Low-grade non-hodgkin lymphomas. Semin Radiat Oncol, 17(3), 198-205. https://doi.org/10.1016/j.semradonc.2007.02.006
Tsimberidou, A. M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W. G., Kantarjian, H., . . . Keating, M. J. (2006). Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107(1), 125-135. https://doi.org/10.1002/cncr.21931
Van Besien, K. (2006). The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev, 20(5), 235-244. https://doi.org/10.1016/j.blre.2006.01.001
van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., . . . Hagenbeek, A. (2006). Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108(10), 3295-3301. https://doi.org/10.1182/blood-2006-05-021113
van Oers, M. H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., . . . Hagenbeek, A. (2010). Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol, 28(17), 2853-2858. https://doi.org/10.1200/JCO.2009.26.5827
Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M. H., Ghielmini, M., Hsu Schmitz, S. F., . . . Shpilberg, O. (2011). Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst, 103(23), 1799-1806. https://doi.org/10.1093/jnci/djr418
Voong, K. R., McSpadden, K., Pinnix, C. C., Shihadeh, F., Reed, V., Salehpour, M. R., . . . Dabaja, B. S. (2014). Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiat Oncol, 9, 94. https://doi.org/10.1186/1748-717x-9-94
Voss, M. H., Lunning, M. A., Maragulia, J. C., Papadopoulos, E. B., Goldberg, J., Zelenetz, A. D., & Horwitz, S. M. (2013). Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk, 13(1), 8-14. https://doi.org/10.1016/j.clml.2012.09.002
Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., . . . Zhang, L. (2016). Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol, 17(1), 48-56. https://doi.org/10.1016/S1470-2045(15)00438-6
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., . . . Blum, K. A. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med, 369(6), 507-516. https://doi.org/10.1056/NEJMoa1306220
Wasterlid, T., Hartman, L., Szekely, E., & Jerkeman, M. (2017). Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol, 35(2), 151-157. https://doi.org/10.1002/hon.2256
Weisenburger, D. D., & Armitage, J. O. (1996). Mantle cell lymphoma-- an entity comes of age. Blood, 87(11), 4483-4494.
Wilkosz, P., Greggains, G. D., Tanbo, T. G., & Fedorcsak, P. (2014). Female reproductive decline is determined by remaining ovarian reserve and age. PLoS One, 9(10), e108343. https://doi.org/10.1371/journal.pone.0108343
Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019). The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 133(16), 1703-1714. https://doi.org/10.1182/blood-2018-11-881268
Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S. H., . . . Meijer, C. J. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood, 105(10), 3768-3785. https://doi.org/10.1182/blood-2004-09-3502
Willemze, R., & Meijer, C. J. (2003). Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am, 17(6), 1319-1332, vii-viii.
Wilson, W. H., Grossbard, M. L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., . . . Balis, F. (2002). Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99(8), 2685-2693.
Wirth, A., Mikhaeel, N. G., Aleman, B. M. P., Pinnix, C. C., Constine, L. S., Ricardi, U., . . . Specht, L. (2020). Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology*Biology*Physics, 107(5), 909-933. https://doi.org/https://doi.org/10.1016/j.ijrobp.2020.03.019
Wittink, H., & Michel, T. H. (red.). (2002). Chronic pain management for physical therapists (2. utg.). Woburn, MA: Elsevier Science.
Wong, J. Y. C., Filippi, A. R., Dabaja, B. S., Yahalom, J., & Specht, L. (2018). Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys, 101(3), 521-529. https://doi.org/10.1016/j.ijrobp.2018.04.071
Wotherspoon, A. C., Doglioni, C., Diss, T. C., Pan, L., Moschini, A., de Boni, M., & Isaacson, P. G. (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342(8871), 575-577.
Wundisch, T., Thiede, C., Morgner, A., Dempfle, A., Gunther, A., Liu, H., . . . Neubauer, A. (2005). Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol, 23(31), 8018-8024. https://doi.org/10.1200/JCO.2005.02.3903
Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y.-X., Tsang, R., & Wirth, A. (2015). Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics, 92(1), 11-31. https://doi.org/https://doi.org/10.1016/j.ijrobp.2015.01.009
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol, 30(18), 2183-2189. https://doi.org/10.1200/JCO.2011.38.0410
Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., Halpern, J. D., & Horning, S. J. (1997). Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89(3), 814-822.
Zaorsky, N. G., Williams, G. R., Barta, S. K., Esnaola, N. F., Kropf, P. L., Hayes, S. B., & Meyer, J. E. (2017). Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev, 53, 47-52. https://doi.org/10.1016/j.ctrv.2016.11.016
Zhou, Z., Sehn, L. H., Rademaker, A. W., Gordon, L. I., Lacasce, A. S., Crosby-Thompson, A., . . . Winter, J. N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123(6), 837-842. https://doi.org/10.1182/blood-2013-09-524108
Zucca, E., Conconi, A., Laszlo, D., Lopez-Guillermo, A., Bouabdallah, R., Coiffier, B., . . . Thieblemont, C. (2013). Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol, 31(5), 565-572. https://doi.org/10.1200/JCO.2011.40.6272
Zucca, E., Roggero, E., Bertoni, F., Conconi, A., & Cavalli, F. (1999). Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol, 10(9), 1023-1033.